维持性血液透析左心室肥厚患者使用芪苈强心胶囊治疗后对血清FGF-23水平和心功能的影响  

Effect of Qiliqiangxin Capsule on Serum FGF-23 level and cardiac function in patients with left ventricular hypertrophy on maintenance hemodialysis

作　　者：彭茜 蒋兰晔 陈美英 周燕霞 Peng Qian;Jiang Lanye;Chen Meiying;Zhou Yanxia(Blood Purification Room,Leliu Hospital,Shunde Hospital,Guangzhou University of Chinese Medicine,Foshan 528322,China)

机构地区：[1]广州中医药大学顺德医院附属勒流医院血液净化室,广东佛山528322

出　　处：《山东第一医科大学（山东省医学科学院）学报》2021年第8期592-594,共3页Journal of Shandong First Medical University ＆ Shandong Academy of Medical Sciences

基　　金：广东省中医药局科研项目(20171303)。

摘　　要：目的探讨维持性血液透析左心室肥厚患者使用芪苈强心胶囊治疗后血清FGF-23(fibroblast growth factor-23,FGF-23)的表达情况以及对心功能的影响。方法选取2017年1月—2018年12月在广州中医药大学顺德医院附属勒流医院血液透析中心维持性血液透析的慢脏肾脏病5期患者42例,根据随机数字法将其分为两组,对照组17例,治疗组25例。对照组患者给予基础治疗;治疗组在对照组基础上给予芪苈强心胶囊治疗,通过与对照组相对比,分析患者经芪苈强心胶囊治疗12周后的心功能改善情况、血清FGF-23变化水平以及患者的左心室质量指数情况,对相关资料进行统计分析。结果治疗组在使用芪苈强心胶囊治疗12周后,合并左心室肥厚的CKD5期患者血清FGF-23水平下降,两组对比差异具有统计学意义(P<0.05);治疗组心功能得到了明显改善,且明显优于对照组,差异有统计学意义(P<0.05)。结论芪苈强心胶囊可以下调CKD5期左心室肥厚患者血清FGF-23水平,并改善其心功能。Objective:To investigate the expression of serum FGF-23(fibroblast growth factor-23,FGF-23)in patients with left ventricular hypertrophy on maintenance hemodialysis after treatment with Qiliqiangxin Capsule and its effect on cardiac function.Methods:Forty-two patients with chronic kidney disease stage 5 who were on maintenance hemodialysis in our hospital's hemodialysis center from January 2017 to December 2018 were selected,and divided into two groups according to the random number method.The control group had 17 cases and the treatment group had 25 cases.Patients in the control group were given basic treatment.The treatment group was given Qiliqiangxin Capsule on the basis of basic treatment.By comparing with the control group,the improvement of cardiac function,the change of serum FGF-23,and the left ventricular mass index of patients after 12 weeks of treatment with Qiliqiangxin Capsule were analyzed,and the relevant data were analyzed statistically.Results:In patients in the treatment group,after 12 weeks of treatment with Qiliqiangxin Capsule,serum FGF-23 levels in CKD stage 5 patients with left ventricular hypertrophy decreased.The difference between the two groups was statistically significant(P<0.05).the cardiac function of the treatment group was significantly improved,and the difference was significantly better than that of the control group.The difference was statistically significant(P<0.05).Conclusion:Qiliqiangxin Capsule can down-regulate the serum FGF-23 level in patients with CKD stage 5 left ventricular hypertrophy and improve their cardiac function.

关 键 词：慢性肾脏病5期 芪苈强心胶囊 FGF-23 左心室肥大 

分 类 号：R692[医药卫生—泌尿科学]